Costs of chronic obstructive pulmonary disease (COPD) in Italy: The SIRIO study (Social Impact of Respiratory Integrated Outcomes)

Respiratory Medicine

Volumn 102, Issue 1, 2008, Pages 92-101

  Dal Negro, R W ^a,d   Tognella, S ^a,d   Tosatto, R ^b   Dionisi, M ^b   Turco, P ^a,d   Donner, C F ^c,d  

^a Ospedale Orlandi   (Italy)

^b GSK   (Italy)

^c Mondo Medico   (Italy)

^d Centro Nazionale Studi di Farmacoeconomia e Farmacoepidemiologia Respiratoria   (Italy)

Author keywords

COPD; Health economics; Healthcare costs

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CONSULTATION; DEMOGRAPHY; DIAGNOSTIC APPROACH ROUTE; DISEASE SEVERITY; EMERGENCY CARE; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH SURVEY; HOSPITAL ADMISSION; HUMAN; MEDICAL SPECIALIST; NATIONAL HEALTH SERVICE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY SYSTEM; SOCIAL ASPECT;

AGED; COST-BENEFIT ANALYSIS; DEMOGRAPHY; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; ITALY; MALE; MODELS, ECONOMIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX;

EID: 36448995094     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.08.001     Document Type: Article

References (30)

1. Murray C.J., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020-Global Burden of Disease Study. Lancet 349 (1997) 1498-1504
2. De Marco R., Accordini S., and Cerveri I. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 59 (2004) 120-125
3. Domingo-Salvany A., Lamarca R., and Ferrer M. Health related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166 (2002) 680-685
4. Fletcher C.M., Peto R., and Tinker C.M. The natural history of chronic bronchitis and emphysema (1976), Oxford University Press, Oxford
5. Vestbo J., and Rasmussen F.V. Respiratory symptoms and FEV! As predictors of hospitalization and medication in the following 12 years due to respiratory disease. Eur Respir J 2 (1989) 710-715
6. Price D, Tinkelman DG, Nordlyke RJ. Severity distribution of COPD in primary care. In: Proceeding of the European respiratory society congress, 2004. Abstract ERS4L1_2562.
7. Dal Negro R., Berto P., Tognella S., and Quareni L. Cost-of-illness of lung disease in the TriVeneto Region, Italy: the GOLD Study. Monaldi Arch Chest Dis 57 (2002) 1-7
8. Rennard S., Decramer M., Calverley P.M.A., et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 20 (2002) 799-805
9. Chapman K.R., et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 27 (2006) 188-207
10. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Executive summary NHLBI/WHO Workshop Report, 2001.
11. Brooks R. With the EuroQol Group-Eurogol: the current state of play. Health Policy 37 (1996) 53-72
12. Gagnon Y.M., Levy A.R., and Spencer M.D. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long acting beta2-agonists in a health maintenance organization. Respir Med 99 (2005) 1534-1545
13. Lucioni C., Donner C.F., and De Benedetto F. I costi della broncopneumopèatia cronica ostruttiva: la fase prospettica dello studio ICE (Italian costs for exacerbations in COPD). Pharmacoeconomics (Italian Research Articles) 7 (2005) 119-134
14. Spencer M., Briggs A.H., and Grossman R.F. Development of an economic modelto assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 23 (2005) 619-637
15. Miravitlles M., Murio C., Guerrero T., and Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 123 (2003) 784-791
16. Wouters E.F. The burden of COPD in the Netherlands: results from the Confronting study. Respir Med 97 Suppl. C (2003) S51-S59
17. Rutten-van Molken M.P., Postma M.J., Joore M.A., Van genugten M.L., Leidl R., and Jager J.C. Current and future medical costs of asthma and chronic obstructive pulmonary disease in the Netherlands. Respir Med 93 (1999) 779-787
18. Jansson S.A., Andersson F., Borg S., Ericsson A., Jonsson E., and Lundback B. Costs of COPD in Sweden according to disease severity. Chest 122 (2002) 1994-2002
19. Simoens S., and Decramer M. Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease. Expert Opin Pharmacother 8 (2007) 633-648
20. Informatore Farmaceutico. Milano: Masson Ed.; 2004.
21. Ministero della Sanità. Tariffe Ambulatoriali Nazionali. Nomenclatore Tariffario delle prestazioni ambulatoriali, DM 22.07.1996, Gazzetta Ufficiale no. 216, 14.09.1996.
22. Ministero della Sanità. Aggiornamento delle tariffe delle prestazioni di assistenza ospedaliera. DM 14.12.1994, Gazzetta Ufficiale, Suppl. Ordinario no. 209, 08.09.1997.
23. Banca d'Italia. Costo di una giornata di lavoro sui cittadini occupati, 2002.
24. Sullivan S.D., Ramsey S.D., and Lee T.A. The economic burden of COPD. Chest 117 Suppl. 2 (2000) 5-9S
25. Viegi G., Scognamiglio A., Baldacci S., et al. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 68 (2001) 4-19
26. Dal Negro R., Rossi A., and Cerveri I. The burden of COPD in Italy: results from the Confronting COPD Survey. Respir Med 97 Suppl. C (2003) 43s-50s
27. Dal Negro R.W., Eandi M., Pradelli L., and Iannazzo S. Cost-effectiveness and health care budget impact in Italy of inhaled corticosteoids and bronchodilators for severe and very severe COPD patients. Int J COPD 2 (2007) 1-8
28. Andersson F., Borg S., Jansson S.A., et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 96 (2002) 700-708
29. Dal Negro R.W., Pomari C., Tognella S., and Micheletto C. Salmeterol & Fluticasone 50/250 mcg bid in combination provides a better long-term control than salmeterol 50 mcg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther 16 (2003) 241-246
30. Miravitlles M., Murio C., Tina Guerrero T., and Gisbert R. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121 (2002) 1449-1455